All In Biotech

Free tool

FAERS Monitor: Cablivi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761112 or its brand name (Cablivi, Caplacizumab-Yhdp). Reports on generic versions are filed under their own applications.

Reports

1,784

Serious

749

42% of reports

Hospitalization

357

Death reported

109

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • product use in unapproved indication619
  • off label use208
  • adamts13 activity decreased161
  • epistaxis133
  • platelet count decreased133
  • fatigue111
  • contusion89
  • thrombotic thrombocytopenic purpura84
  • headache83
  • injection site pain82
  • condition aggravated80
  • adamts13 activity abnormal73
  • injection site bruising70
  • hospitalisation50
  • gingival bleeding49

Reports by year received

View as table
YearReports
2019132
2020194
2021240
2022269
2023256
2024236
2025270
2026187

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,375 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
adamts13 activity abnormalSignal7347858.228632.4681,591
adamts13 activity decreasedSignal16119386.815146.91,173,591
thrombotic thrombocytopenic purpuraSignal84287.9233.023,169
gingival bleedingSignal4942.432.21,936
product use in unapproved indicationSignal61929.527.717,186
epistaxisSignal13321.017.82,518
platelet count decreasedSignal13314.712.51,695
contusionSignal8910.98.9794
injection site bruisingSignal7010.48.2584
hospitalisationSignal503.82.9103
injection site painSignal823.22.6120
condition aggravatedSignal803.12.5114
off label useSignal2082.82.5249
fatigue1111.71.431
headache831.61.317

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.